[Acne, dermatologists, cosmetics and the PP (publicity product)].
Explore the source record for details and available documents.
Biomedical subjects
Publications and source records attributed to F Poli.
Explore the source record for details and available documents.
BACKGROUND: specific immunotherapy for Hymenoptera Venom (VIT) is considered a life-saving treatment in insect sting allergy. A few studies with depot VIT have been published, but they are mainly focussed on patients sensitized to Apis. METHODS: this retrospective study was designed to evaluate both efficacy and safety of depot VIT for Vespula. Thirty-six patients (age range 6-73 years) with a history of systemic reactions (grade III to IV according to Mueller) after a Vespula sting, and specific sera IgE RAST to Vespula at least class 2, were administered a depot preparation of venom reaching 50 microgram as monthly maintenance dose. After the first year the maintenance dose was administered every other month. Thirty-three patients were treated for a minimum of 5 years. Reactions to any new field sting of the relevant insect were recorded during the treatment and for 6 to 24 months after its interruption. RESULTS: the treatment showed an excellent tolerance, with only a few local side effects. Thirteen patients (11 Grade IV according to Mueller before VIT) under treatment showed only local reactions after each field sting (18 field stings in total) by the relevant insect. Four patients (3 Grade IV according to Mueller before VIT) had a total of 6 field stings after the interruption of the 5-year treatment, with only local reactions. CONCLUSIONS: according to our results, and in agreement with previous published studies, VIT for Vespula spp. with depot extracts has an excellent tolerance and is clinically effective.
Explore the source record for details and available documents.
Thirty one patients with suspicion of asthma due to food allergy (lack of correlation between allergic sensitivity and asthmatic attacks, association of clinical features suggestive of food allergy, no response to the pharmacological treatment) received an elimination diet. A second group (control group) of 51 asthmatic patients were enrolled in the study for a better evaluation of the diagnostic significance of blood eosinophil counts in food-induced asthma. 29-31 patients who took a variable oligoallergenic diet had a baseline blood eosinophilia greater than 600/mm3 (range 600-2100/mm3). Eosinophil count after an appropriate diet showed an early significant fall which preceded the improvement of symptoms. Only 10 patients had not a valuable improvement from the diet. The post diet change of spirometric values was significant. There was no significant difference between subjects with an eosinophil count greater than 1000/mm3 vs. less than 1000/mm3 with regard to both inhalant and food skin prick tests. On the other hand, the group with blood eosinophilia greater than 1000/mm3 had a significant correlation with the presence of persistent asthma (persistent alteration of forced expiratory volumes verified in asymptomatic phases of the disease) as with the anamnestic or actual report of eczema or other clinical manifestations of food allergy. Blood eosinophil count showed to be essential in the management of patients with a suspicion of asthma due to food allergy.
Data from 34 patients were included in the analysis of this open group comparative study comparing a controlled release theophylline given twice daily with immediate release aminophylline given four times daily. The treatment period was of eight weeks duration. There was no significant difference between treatments in clinical assessments of asthma severity or pulmonary function tests. Similarly there were no significant differences between treatments in diary card assessments of asthma symptoms or PERF. Serum theophylline levels were measured prior to the morning dose of test treatment and 2 or 5 hours later, respectively for patients taking immediate release (IR) or controlled release (CR) preparations, at each clinic visit. There was no significant difference between treatments in serum theophylline levels fluctuations, although the dosing interval (12 hours) was twice as long for CR formulation. Six patients reported unusual symptoms, two in the CR group (headache, gastric discomfort) four in the aminophylline group (three headache, one headache and vomiting).
BACKGROUND: Traditional ABO blood group serology is based on the immunoreactivity of antisera with the carbohydrate A, B and H antigens. Progress in the molecular biology of the ABO system has recognized the molecular basis of the red cell (RBC) antigens and has provided a genetic model for ABO polymorphism at the molecular level. Recently, this genetic model was tested in a large number of individuals. MATERIALS AND METHODS: In this study we applied DNA analysis to determine the frequency of ABO genotypes in a group of blood donors for whom the ABO type was known. Two hundred and fifty healthy Italian blood donors were analyzed using polymerase chain reaction (PCR) to amplify two different regions of genomic DNA, each of which contained a different nucleotide polymorphism. The amplified product was digested with 4 restriction enzymes that revealed differences among A, B and O individuals. To analyze the genes at polymorphic sites 261 and 703 we used the restriction enzymes BstE II and Kpn I, and Hpa II and Alu I and compared the PCR determined genotypes to serologically determined phenotypes. RESULTS AND CONCLUSIONS: The results were consistent for all unrelated individuals; however, 2 of 100 individuals with the 0 phenotype carried one allele that differed from the proposed genetic model. This novel O allele, termed 0(2) by Yamamoto et al., was found in our series with a frequency of 1%. The blood group AB0 genotype of 250 healthy Italian blood donors was: 13 AA/AO(2), 37 AO(1), 11 BB, 39 B0(1), 50 AB, 98 0(1)0(1) and 2 0(1)0(2). This method should be applicable not only in forensic medicine but also in immunohematology when serology fails.
We applied a polymerase chain reaction-sequence specific primer (PCR-SSP) method developed by other researchers to study 4 families of newborns with neonatal alloimmune thrombocytopenia (NAITP) in which serology had provided inconclusive human platelet antigen (HPA) typing data. This method allowed for the identification of the newborn HPAs which were incompatible with their respective mothers. They were HPA-2b, -1b, -3a, and -5b. This PCR-SSP is a useful tool for improving the ability to identify the incompatible HPA in NAITP.
This study concerns 46 chronically mentally ill patients living in community support systems. Their quality of life was measured with a validated questionnaire: the "Subjective Quality of Life Questionnaire" ("SQLP"). Both patients and their care givers separately completed the same version of the questionnaire. This study first shows the feasibility of such inquiries with chronically mentally ill patients. It gives a description of the patient's feeling which is different from the usual medical point of view. The life domains the patient is very satisfied with are mostly restricted to food, material conditions, and relationship with the care-givers, but exclude the other relationships. Our data also allow to estimate the degree of agreement and disagreement between the care-givers and their patients.